These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 18201189)

  • 1. Some recent developments regarding arthropathy and inhibitors in haemophilia.
    Rodriguez-Merchan EC
    Haemophilia; 2008 Mar; 14(2):242-7. PubMed ID: 18201189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations.
    Jiménez-Yuste V; Alvarez MT; Martín-Salces M; Quintana M; Rodriguez-Merchan C; Lopez-Cabarcos C; Velasco F; Hernández-Navarro F
    Haemophilia; 2009 Jan; 15(1):203-9. PubMed ID: 19149850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
    Steen Carlsson K; Astermark J; Donfield S; Berntorp E
    Thromb Haemost; 2008 Jun; 99(6):1060-7. PubMed ID: 18521509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of haemophilic arthropathy in haemophilic children with inhibitors.
    Rodriguez-Merchan EC
    Haemophilia; 2008 Nov; 14 Suppl 6():1-3. PubMed ID: 19134025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experiences in the prevention of arthropathy in haemophila patients with inhibitors.
    Jimenez-Yuste V; Rodriguez-Merchan EC; Alvarez MT; Quintana M; Martin-Salces M; Hernandez-Navarro F
    Haemophilia; 2008 Nov; 14 Suppl 6():28-35. PubMed ID: 19134031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term secondary prophylaxis with recombinant activated factor VII (rFVIIa) in haemophilia A with inhibitors: a case report.
    Kubisz P; Plamenová I; Stasko J; Dobrotová M; Hollý P
    Thromb Haemost; 2010 Apr; 103(4):868-70. PubMed ID: 20135075
    [No Abstract]   [Full Text] [Related]  

  • 7. Prophylaxis in haemophilia with inhibitors: update from international experience.
    Carcao M; Lambert T
    Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When should prophylaxis therapy in inhibitor patients be considered?
    Young G; Auerswald G; Jimenez-Yuste V; Konkle BA; Lambert T; Morfini M; Santagostino E; Blanchette V
    Haemophilia; 2011 Sep; 17(5):e849-57. PubMed ID: 21418444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs.
    Santagostino E; Morfini M; Auerswald GK; Benson GM; Salek SZ; Lambert T; Salaj P; Jimenez-Yuste V; Ljung RC
    Haemophilia; 2009 Sep; 15(5):983-9. PubMed ID: 19712172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of arthropathy in haemophilia - intensive on-demand treatment, UK perspective.
    Lee CA
    Haemophilia; 2008 Nov; 14 Suppl 6():11-5. PubMed ID: 19134027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
    Young G; Shafer FE; Rojas P; Seremetis S
    Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors.
    Ewing N; Escuriola-Ettingshausen C; Kreuz W
    Haemophilia; 2015 May; 21(3):358-364. PubMed ID: 25603840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
    Valentino LA; Cooper DL; Goldstein B
    Haemophilia; 2011 Jul; 17(4):579-89. PubMed ID: 21294815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding.
    Economou M; Teli A; Tzantzaroudi A; Tsatra I; Zavitsanakis A; Athanassiou-Metaxa M
    Haemophilia; 2008 Mar; 14(2):390-1. PubMed ID: 18194305
    [No Abstract]   [Full Text] [Related]  

  • 15. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors.
    Young G; McDaniel M; Nugent DJ
    Haemophilia; 2005 May; 11(3):203-7. PubMed ID: 15876264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bypassing agent prophylaxis for preventing arthropathy in patients with inhibitors.
    Ewenstein BM; Wong WY; Schoppmann A
    Haemophilia; 2010 Jan; 16(1):179-80. PubMed ID: 19702885
    [No Abstract]   [Full Text] [Related]  

  • 17. How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors.
    Leissinger CA; Singleton T; Kruse-Jarres R
    Blood; 2015 Jul; 126(2):153-9. PubMed ID: 25827834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry.
    Furukawa S; Nogami K; Ogiwara K; Yada K; Minami H; Shima M
    J Thromb Haemost; 2015 Jul; 13(7):1279-84. PubMed ID: 25903848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?
    Hedner U
    Haemophilia; 2008 Nov; 14 Suppl 6():23-7. PubMed ID: 19134030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors in haemophilia A: current management and open issues.
    Haya S; Moret A; Cid AR; Cortina V; Casaña P; Cabrera N; Aznar JA
    Haemophilia; 2007 Dec; 13 Suppl 5():52-60. PubMed ID: 18078398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.